logo
Overview
Discover
Watchlists
Portfolios
Heatmap
Sectors
Trendscore
Performers
Alerts
Options
Earnings
Screeners
Scanners
Backtests
Strategies
Comparisons
Charts
Sign in
Sectors
MNOV
MediciNova, Inc.
1.44
2 x 0.95
2 x 1.71
bid
ask
+
0.00
0.00%
2 @ 04:10 PM
1.43 -0.01 (0.35%)
Ytd9.54%
1y9.54%
1.43
day range
1.46
1.17
52 week range
1.96
Open1.43Prev Close1.44Low1.43High1.46Mkt Cap70.63M
Vol18.67KAvg Vol49.59KEPS-0.21P/EN/AForward P/E-0.06
Beta0.77Short Ratio11.20Inst. Own21.30%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning11-1250-d Avg1.36200-d Avg1.431yr Est8.33

MNOV News

MediciNova (MNOV) Reports Q2 Loss, Tops Revenue Estimates
zacks.com
MediciNova (MNOV) Reports Q2 Loss, Tops Revenue Estimates

MediciNova (MNOV) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estim

MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients
globenewswire.com
MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program

LA JOLLA, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company tr

MediciNova CEO Provides Shareholder Update
globenewswire.com
MediciNova CEO Provides Shareholder Update

LA JOLLA, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company tr
benzinga.com
MediciNova Receives U.S. Patent Office Notice Of Allowance Covering The Use Of Ibudilast In The Trea

Once issued, this patent is expected to expire no earlier than September 2042. The allowed claims co

MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment
globenewswire.com
MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with An

LA JOLLA, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company tr

MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
globenewswire.com
MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of

LA JOLLA, Calif. , May 26, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc. , a biopharmaceutical company t

New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation
globenewswire.com
New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medic

LA JOLLA, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company t

MediciNova (NASDAQ:MNOV) Shares Cross Above 200 Day Moving Average – Here’s What Happened
defenseworld.net
MediciNova (NASDAQ:MNOV) Shares Cross Above 200 Day Moving Average – Here’s What Happened

MediciNova, Inc. (NASDAQ: MNOV - Get Free Report) crossed above its 200-day moving average during tr

This Qualcomm Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday
benzinga.com
This Qualcomm Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday

This Cohu Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
benzinga.com
This Cohu Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Analysts changed outlook for top names like SUNB, SLDP, ZVRA, COHU, and MNOV. See analyst ratings pa
benzinga.com
HC Wainwright & Co. Initiates Coverage On MediciNova with Buy Rating, Announces Price Target of $10

HC Wainwright & Co. analyst Lander Egaña Gorroño initiates coverage on MediciNova (NASDAQ:MNO

MediciNova to Participate at the 38th Annual ROTH Conference
globenewswire.com
MediciNova to Participate at the 38th Annual ROTH Conference

LA JOLLA, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company t

MediciNova, Inc. (NASDAQ:MNOV) Given Consensus Recommendation of “Moderate Buy” by Brokerages
defenseworld.net
MediciNova, Inc. (NASDAQ:MNOV) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of MediciNova, Inc. (NASDAQ: MNOV - Get Free Report) have earned an average rating of "Modera

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com
D. Boral Capital Maintains Buy on MediciNova, Maintains $9 Price Target

D. Boral Capital analyst Jason Kolbert maintains MediciNova (NASDAQ:MNOV) with a Buy and maintain
benzinga.com
MediciNova Reveals That As Of The End Of January 2026, 12 Sites In The US Are Activated And 100 Pati

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and t

MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients
globenewswire.com
MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating

LA JOLLA, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company tr

MediciNova, Inc. (NASDAQ:MNOV) Receives $7.00 Average Target Price from Analysts
defenseworld.net
MediciNova, Inc. (NASDAQ:MNOV) Receives $7.00 Average Target Price from Analysts

Shares of MediciNova, Inc. (NASDAQ: MNOV - Get Free Report) have received an average recommendation

VivoSim Labs (NASDAQ:VIVS) and MediciNova (NASDAQ:MNOV) Head-To-Head Analysis
defenseworld.net
VivoSim Labs (NASDAQ:VIVS) and MediciNova (NASDAQ:MNOV) Head-To-Head Analysis

MediciNova (NASDAQ: MNOV - Get Free Report) and VivoSim Labs (NASDAQ: VIVS - Get Free Report) are bo

2026 New Year's Greetings from the CEO
globenewswire.com
2026 New Year's Greetings from the CEO

LA JOLLA, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company tr
benzinga.com
D. Boral Capital Maintains Buy on MediciNova, Maintains $9 Price Target

D. Boral Capital analyst Jason Kolbert maintains MediciNova (NASDAQ:MNOV) with a Buy and maintain
benzinga.com
MediciNova Completes Patient Enrollment in Mid-Stage Trial for Chemotherapy Nerve Damage

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and t

MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy
globenewswire.com
MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Preventio

LA JOLLA, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company tr
benzinga.com
D. Boral Capital Maintains Buy on MediciNova, Maintains $9 Price Target

D. Boral Capital analyst Jason Kolbert maintains MediciNova (NASDAQ:MNOV) with a Buy and maintain

MediciNova Announces Update and Basic Characteristic Randomized Patients' of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND
globenewswire.com
MediciNova Announces Update and Basic Characteristic Randomized Patients' of Phase 2/3 Clinical Tria

LA JOLLA, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company li

MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor
globenewswire.com
MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor

LA JOLLA, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company tr
benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session

MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards
globenewswire.com
MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awar

LA JOLLA, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company tr
benzinga.com
D. Boral Capital Maintains Buy on MediciNova, Maintains $9 Price Target

D. Boral Capital analyst Jason Kolbert maintains MediciNova (NASDAQ:MNOV) with a Buy and maintain
benzinga.com
MediciNova Completes Patient Enrollment In Its Phase 2 MN-001-NATG-202 Trial Of MN-001 (Tipelukast)

The MN-001-NATG-202 study is a multi-center, randomized, double-blind, placebo-controlled trial to e
benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
benzinga.com
D. Boral Capital Maintains Buy on MediciNova, Maintains $9 Price Target

D. Boral Capital analyst Jason Kolbert maintains MediciNova (NASDAQ:MNOV) with a Buy and maintain

Why Amazon Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket
benzinga.com
Why Amazon Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket

Why Did MediciNova Stock (MNOV) Jump Over 87% In After-Hours Trading?
benzinga.com
Why Did MediciNova Stock (MNOV) Jump Over 87% In After-Hours Trading?

MediciNova shares soared over 87% in after-hours trading on Thursday following the publication of pr

MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication
globenewswire.com
MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Pub

Study published in the Journal of Atherosclerosis and Thrombosis demonstrates tipelukast (MN-001 and

MediciNova to Present at the LD Micro Main Event XIX Investor Conference
globenewswire.com
MediciNova to Present at the LD Micro Main Event XIX Investor Conference

LA JOLLA, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company tr
benzinga.com
D. Boral Capital Maintains Buy on MediciNova, Maintains $9 Price Target

D. Boral Capital analyst Jason Kolbert maintains MediciNova (NASDAQ:MNOV) with a Buy and maintain
benzinga.com
MediciNova Completes Patient Enrollment In Phase 2/3 Clinical Trial, COMBAT-ALS For Treatment Of Amy

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and t
benzinga.com
MediciNova Issues Shareholder Update; Secures $30M SEPA To Advance R&D As COMBAT-ALS Trial Hits Enro

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and t
benzinga.com
MediciNova Q2 EPS $(0.07) Beats $(0.10) Estimate, Sales $134.599K

MediciNova (NASDAQ:MNOV) reported quarterly losses of $(0.07) per share which beat the analyst conse
benzinga.com
D. Boral Capital Maintains Buy on MediciNova, Maintains $9 Price Target

D. Boral Capital analyst Jason Kolbert maintains MediciNova (NASDAQ:MNOV) with a Buy and maintain
benzinga.com
B. Riley Securities Maintains Buy on MediciNova, Lowers Price Target to $5

B. Riley Securities analyst Mayank Mamtani maintains MediciNova (NASDAQ:MNOV) with a Buy and lowe
benzinga.com
MediciNova Q1 EPS $(0.06) Beats $(0.14) Estimate

MediciNova (NASDAQ:MNOV) reported quarterly losses of $(0.06) per share which beat the analyst conse
benzinga.com
D. Boral Capital Maintains Buy on MediciNova, Maintains $9 Price Target

D. Boral Capital analyst Jason Kolbert maintains MediciNova (NASDAQ:MNOV) with a Buy and maintain
benzinga.com
Reported Earlier, MediciNova Announces First Enrollment In NIH-Supported EAP Trial To Assess MN-166

This significant milestone marks the beginning of a critical trial aimed at providing access to MN-1
benzinga.com
D. Boral Capital Maintains Buy on MediciNova, Maintains $9 Price Target

D. Boral Capital analyst Jason Kolbert maintains MediciNova (NASDAQ:MNOV) with a Buy and maintain
benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga.com
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving I